- Home
- SPHL vs ATNM Comparison
SPHL vs ATNM Comparison
Compare SPHL & ATNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPHL
- ATNM
- Stock Information
- Founded
- SPHL 2002
- ATNM 2000
- Country
- SPHL Singapore
- ATNM United States
- Employees
- SPHL N/A
- ATNM N/A
- Industry
- SPHL Homebuilding
- ATNM Biotechnology: Pharmaceutical Preparations
- Sector
- SPHL Consumer Discretionary
- ATNM Health Care
- Exchange
- SPHL Nasdaq
- ATNM Nasdaq
- Market Cap
- SPHL 54.5M
- ATNM 56.5M
- IPO Year
- SPHL 2024
- ATNM N/A
- Fundamental
- Price
- SPHL $3.12
- ATNM $1.40
- Analyst Decision
- SPHL
- ATNM Strong Buy
- Analyst Count
- SPHL 0
- ATNM 4
- Target Price
- SPHL N/A
- ATNM $8.75
- AVG Volume (30 Days)
- SPHL 330.5K
- ATNM 342.1K
- Earning Date
- SPHL 02-21-2025
- ATNM 11-14-2024
- Dividend Yield
- SPHL N/A
- ATNM N/A
- EPS Growth
- SPHL 413.11
- ATNM N/A
- EPS
- SPHL 0.09
- ATNM N/A
- Revenue
- SPHL $11,020,429.00
- ATNM $81,000.00
- Revenue This Year
- SPHL N/A
- ATNM $138.42
- Revenue Next Year
- SPHL N/A
- ATNM $19,479.88
- P/E Ratio
- SPHL $35.66
- ATNM N/A
- Revenue Growth
- SPHL 112.84
- ATNM N/A
- 52 Week Low
- SPHL $2.71
- ATNM $1.10
- 52 Week High
- SPHL $7.16
- ATNM $10.24
- Technical
- Relative Strength Index (RSI)
- SPHL N/A
- ATNM 56.03
- Support Level
- SPHL N/A
- ATNM $1.18
- Resistance Level
- SPHL N/A
- ATNM $1.48
- Average True Range (ATR)
- SPHL 0.00
- ATNM 0.10
- MACD
- SPHL 0.00
- ATNM 0.01
- Stochastic Oscillator
- SPHL 0.00
- ATNM 75.00
About SPHL Springview Holdings Ltd Class A Ordinary Shares
Springview Holdings Ltd is a company that conducts its operations through its indirect wholly-owned subsidiary which designs and constructs residential and commercial buildings in Singapore. It also provides four main types of works which includes new construction, reconstruction, Additions and Alterations (A&A), and other general contracting services such as renovation and design consultation.
About ATNM Actinium Pharmaceuticals Inc. (Delaware)
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.